Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study

被引：4
|
作者：
Lalanne, Sebastien [1 ,2 ]
Jezequel, Caroline [3 ]
Tron, Camille [1 ,2 ]
Verdier, Marie-Clemente [1 ,2 ]
Mercerolle, Marion [4 ]
Pronier, Charlotte [5 ]
Guyader, Dominique [2 ,3 ]
Lemaitre, Florian [1 ,2 ]
机构：
[1] Rennes Univ Hosp, Fac Med, Dept Biol & Clin Pharmacol, Rennes, France
[2] Inserm, CIC P Clin Invest Ctr 1414, Rennes, France
[3] Rennes Univ Hosp, Liver Dis Unit, Rennes, France
[4] Rennes Univ Hosp, Dept Pharm, Rennes, France
[5] Rennes Univ Hosp, Dept Virol, Rennes, France
来源：
THERAPEUTIC DRUG MONITORING | 2020年 / 42卷 / 02期
关键词：
sofosbuvir; velpatasvir; crushing; pharmacokinetics; exposure;
D O I：
10.1097/FTD.0000000000000718
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg). As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir-velpatasvir tablets on drug absorption and global exposure.
引用
收藏
页码：163 / 164
页数：2
相关论文
共 50 条
  • [21] Real-world impact of a subsidy decision of sofosbuvir-velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes
    Tan, Chee-Kiat
    Luo, Xue-Shi
    Ong, Benjamin Shao-Kiat
    Lin, Liang
    Ng, Kwong-Hoe
    JGH OPEN, 2023, 7 (01): : 48 - 54
  • [22] Therapeutic Drug Monitoring-Guided Combination Alemtuzumab and Plasmapheresis for Refractory Acute Lung Allograft Dysfunction Rescue Therapy
    Wright, R. C.
    Karin, A.
    Partovi, N.
    Marsh, R.
    Bergeron, C.
    Choi, J.
    Kapasi, A.
    Levy, R. D.
    Samuels, J.
    Wilson, J.
    Yee, J.
    Nador, R. G.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S417 - S417
  • [23] Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial
    Catalina Gómez-Arango
    Inigo Gorostiza
    Eduardo Úcar
    Maria Luz García-Vivar
    Clara Eugenia Pérez
    Juan Ramon De Dios
    Belen Alvarez
    Ana Ruibal-Escribano
    Claudia Stoye
    Margarida Vasques
    Joaquin Belzunegui
    Antonio Escobar
    Ziortza Trancho
    Ainhoa Ruiz del Agua
    Lorena Del Rio
    Cristina Jorquera
    Eli Diez
    Antonio Martínez
    Daniel Nagore
    Rheumatology and Therapy, 2021, 8 : 1323 - 1339
  • [24] Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial
    Gomez-Arango, Catalina
    Gorostiza, Inigo
    Ucar, Eduardo
    Garcia-Vivar, Maria Luz
    Perez, Clara Eugenia
    De Dios, Juan Ramon
    Alvarez, Belen
    Ruibal-Escribano, Ana
    Stoye, Claudia
    Vasques, Margarida
    Belzunegui, Joaquin
    Escobar, Antonio
    Trancho, Ziortza
    Ruiz del Agua, Ainhoa
    Del Rio, Lorena
    Jorquera, Cristina
    Diez, Eli
    Martinez, Antonio
    Nagore, Daniel
    RHEUMATOLOGY AND THERAPY, 2021, 8 (03) : 1323 - 1339
  • [25] Clinical effectiveness and safety of sofosbuvir-velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial
    Sayad, Babak
    Mehrabi, Masomeh
    Khodarahmi, Reza
    Najafi, Farid
    Miladi, Ronak
    Afshar, Zeinab Mohseni
    Mansouri, Feizollah
    Shirvani, Maria
    Salimi, Mehdi
    Shadmani, FatemehKhosravi
    JOURNAL OF REPORTS IN PHARMACEUTICAL SCIENCES, 2021, 10 (02): : 294 - 316
  • [26] Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity
    Cusumano, Jaclyn A.
    Klinker, Kenneth P.
    Huttner, Angela
    Luther, Megan K.
    Roberts, Jason A.
    LaPlante, Kerry L.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (14) : 1104 - 1112
  • [27] Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection
    Brieva, Teresa
    Rivero, Antonio
    Rivero-Juarez, Antonio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (04) : 483 - 490
  • [28] Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis
    Bhat, Mohammad Ashraf
    Mir, Aadil Nabi
    Parry, Manzoor Ahmad
    Parray, Irshad Ahmad
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2023, 34 (06) : 570 - 575
  • [29] Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
    Wei, Lai
    Lim, Seng Gee
    Xie, Qing
    Kinh Nguyen Van
    Piratvisuth, Teerha
    Huang, Yan
    Wu, Shanming
    Xu, Ming
    Tang, Hong
    Cheng, Jun
    Hung Le Manh
    Gao, Yanhang
    Mou, Zhuangbo
    Sobhonslidsuk, Abhasnee
    Dou, Xiaguang
    Thongsawat, Satawat
    Nan, Yuemin
    Chee Kiat Tan
    Ning, Qin
    Hoi Poh Tee
    Mao, Yimin
    Stamm, Luisa M.
    Lu, Sophia
    Dvory-Sobol, Hadas
    Mo, Hongmei
    Brainard, Diana M.
    Yang, Yong-Feng
    Dao, Long
    Wang, Gui-Qiang
    Tanwandee, Tawesak
    Hu, Peng
    Tangkijvanich, Pisit
    Zhang, Lunli
    Gao, Zhi Liang
    Lin, Feng
    Thi Tuyet Phuong Le
    Shang, Jia
    Gong, Guozhong
    Li, Jun
    Su, Minghua
    Duan, Zhongping
    Mohamed, Rosmawati
    Hou, Jin Lin
    Jia, Jidong
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (02): : 127 - 134
  • [30] Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection
    Asselah, Tarik
    Shafran, Stephen D.
    Bourgeois, Stefan
    Lai, Ching-Lung
    Mathurin, Philippe
    Willems, Bernard
    Nguyen, Mindie H.
    Davis, Mitchell N.
    Huang, K. C.
    Svarovskaia, Evguenia
    Osinusi, Anu
    McNally, John
    Brainard, Diana M.
    Shaikh, Obaid S.
    Tran, Tram T.
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (10) : 1229 - 1232
12345